US Dollar Near Two-Month Low as Markets Await Inflation Data 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
Asian Stocks Rise as Weak US Jobs Data Eases Fed Rate Hike Fears 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Gold Prices Rise as Fed Rate Hike Bets Ease 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Johnson & Johnson may be divided soon as there are plans to split it to become two separate companies. With the division, one will operate the pharmaceutical business while the other will be for the consumer products.
Johnson & Johnson revealed its plans to split up its consumer products and medical device operations late last week. It said it would be forming two publicly traded companies, and this news reportedly triggered an increase in the company’s shares after the figures went higher in premarket trading.
The move will separate J&J’s household products unit that makes leading brands such as Neutrogena, Aveeno, and Listerine, from its unit that makes and sells medical devices like AI and robotics and prescription drugs, including the COVID-19 vaccine.
The separation process is expected to be completed within 18 to 24 months. Based on the reports, the medical device unit will be retaining the Johnson & Johnson brand name, and the incoming chief executive officer, Joaquin Duato, will be leading this newly-formed company.
CNBC reported that for the consumer side of the business, outgoing CEO, Alex Gorsky, said they have not decided on its name yet.
“Following a comprehensive review, the board and management team believe that the planned separation of the consumer health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth,” Gorsky said in a statement regarding the split of the firm. “Most importantly – improve healthcare outcomes for people around the world.”
He added that the decision to separate the company into two was approved by the board after discussions that have been going on for some time already. They concluded it was a good step to take because they think it would bring numerous opportunities to stakeholders.
As per Los Angeles Times, the executives of Johnson & Johnson told analysts that the split of the company would make each business more adept in adapting to its respective markets. Gorsky stated the division will also address segments that “have evolved as fundamentally different businesses.” Meanwhile, Duato is set to replace Gorsky as CEO in January 2022.
